Join us in forwarding the study of biology & transforming diagnostics

Revealing the Last Dark Space in the Central Dogma

MesoRNA’s technology provides sequencing, characterization, and bioinformatics for RNAs between 30 and 300 nucleotides, mesoRNAs: tRNA, snRNA, snoRNA, rRNA, mt-RNAs, Y RNA, vtRNA, SRP RNA

Our patented technology, MSR-seq, captures five simultaneous measurements: sequence, abundance epitranscriptomic modifications, charging and fragmentation, providing depth to research in this field.

Building on the legacies of the pioneering scientists who decoded DNA, untangled complexities of epigenetics, and sequenced mRNA, our project aims to further the frontier of genomics.

MesoRNAs—those between 35 and 300 nucleotides—make up 85% of the nucleic acids in humans by molarity, yet remain enigmatic due to historical, technological constraints.

The company, MesoRNA, aims to demystify this area of research by offering the first standardized sequencing & analyzation approach for this class of RNAs.

The basis of MesoRNA’s product comes from patented technology, MSR-seq, from the University of Chicago’s Tao Pan Lab, a leader in the field of tRNA and epitranscriptomic research

mesoRNAs are vital to foundational cellular processes and protein synthesis

Where researchers find gaps between mRNA and the proteome, mesoRNAs complete the story.


By studying and understanding MesoRNAs, we hope to unlock answers and have far-reaching positive effects on treating many diseases with implications of mRNAs.

The list of diseases that could be impacted is long: breast cancer, colon cancer, lung cancer, prostate cancer, neurological disease, infection, antibiotic resistance cardiac disease, and rare diseases.

Our Offerings

  • End-to-End Service Lab

  • Coming soon: Kits with bioinformatics and analytics

Founded in September 2023, our team combines cutting-edge expertise in tRNA, mesoRNAs, epitranscriptomics, and bioinformatics with seasoned entrepreneurial leadership.

More about us

OUR MISSION

to revolutionize genomics.